STUDresearch · Non-peptide
Clomiphene
Also known as
Clomiphene citrate · Clomid (brand) · Clomifene (INN-style spelling) · Serophene (historical brand discussion) · CC / Clom (clinic and forum shorthand) · Clomiphene citrate USP 50 mg tablets
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Lots of talk
Systemic
Oral
Hormone modulators
Systemic oral SERM — a mixture of enclomiphene and longer-persisting zuclomiphene changes hypothalamic/pituitary estrogen feedback.
What people say
Clomiphene is an oral SERM mixture of enclomiphene and longer-persisting zuclomiphene. Female ovulation induction is labeled; male testosterone, fertility and PCT use are off-label.
Doses people talk about
These amounts describe records and forum culture. They are not a personal sequence, recommendation or equivalence across indications.
How it may feel
Responses are mixed: some report earlier energy or libido improvement and stronger labs, while others report flat benefit, libido loss, mood changes or prolonged recovery after stopping.
Forum PCT chart range25–100 mg/day oral in multi-week charts
Historical forum templates vary widely and may include other SERMs or hCG; retained as descriptive culture, not an executable taper.
Male off-label clinic discussion25 mg EOD–50 mg/day oral
Repeated observational/clinic band; not a male FDA indication and not interchangeable with pure enclomiphene. Some infertility write-ups separately discuss ~100 mg/day as an upper amount, not a recommended ceiling.
Female labeled initial course50 mg/day oral × 5 days
One tablet daily for the labeled ovulation-induction course.
Female labeled later course100 mg/day oral × 5 days
Only as a subsequent labeled course after no ovulation on 50 mg; multiple-pregnancy and ovarian risks remain.
Half-life & effect duration
- Half-life in the body
- Mixture · historical summariesAbout 5 days; some give effective ranges of 10–14 days
- Enclomiphene isomer · reported estimateAbout 10–10.5 hours
- Zuclomiphene isomer · reported estimatesAbout 30–50 days
- Felt duration people report
- Positive accountEarly benefit dulled by about 6 weeks
- Other accountsPositive effects, no benefit, or severe mood changes
- After stoppingMood recovery reports range from about a month to much longer
Cycles people discuss
The labeled female course is five days. Male clinic use may be continuous with monitoring, while forum PCT blocks are separate off-label culture and are not a validated universal schedule.
Timing
Community notes describe a consistent time per oral dose, with or without food. Daily versus every-other-day male schedules are a separate discussion from the labeled five-day female course tied to menstrual-cycle timing.
Stacks
Tamoxifen, hCG and aromatase inhibitors appear in off-label fertility or PCT discussions; combinations add distinct mechanisms, risks and attribution problems.
Access talk
Generic 50 mg scored Clomid/tabs are the cheap shelf: Split for 25 mg. This is the FDA-labeled female ovulation product used off-label in men — not a male TRT brand.
Labs people mention
First male panel (~4–6 weeks): Morning total T, free T, LH, FSH, sensitive estradiol, SHBG, CBC/hematocrit, lipids. Clinics often recheck every 3–6 months once stable.
Watch for
Vision (stop-and-evaluate): Blurred vision, spots/scotomata, flashes, or light sensitivity — classic SERM caution for clomiphene; labeled and clinic guidance is to discontinue and get evaluated if visual symptoms appear or persist. Male series put visual changes in roughly the ~1–2% band.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No single dependable composite terminal half-life is established for the mixture by the checked sources.
The label says zuclomiphene can remain detectable longer than one month and radiolabel can appear in feces for six weeks. The single-dose isomer study could not derive conventional terminal half-lives from flat terminal profiles.
Detectability, radiolabel recovery, hormone effects and subjective recovery are different endpoints; female single-dose data do not define chronic male kinetics.
- Clomiphene citrate tablets — FDA label (opens in a new tab)Clinical pharmacology, warnings and dosage: isomer mixture; zuclomiphene detectable longer than one month; fecal radioactivity six weeks; labeled 50 mg then 100 mg five-day ovulation-induction courses; visual warning.Female infertility label. It does not approve male hypogonadism or PCT use and does not provide a clean composite or isomer-specific terminal half-life.
- Single-dose pharmacokinetics of clomiphene isomers (opens in a new tab)Original article printed pp. 147–154: nine women with PCOS, one 50 mg oral dose on cycle day 2, sampled through cycle day 21 / 456 hours after dosing. Table II (p.151) gives separate En/Zu parameters, including mean En Tmax 3 hours; discussion p.153 says flat long tails prevented reliable terminal half-life, clearance, volume and MRT estimates.Small single-dose study in women with PCOS; one patient retained detectable enclomiphene to 456 hours. Not chronic male-use kinetics, felt duration or a dosing-interval study.
Felt duration people report
The inspected accounts do not establish a dependable per-dose felt window or recovery time.
One 25 mg-EOD report described stronger labs and early benefit that dulled by six weeks. Other same-author follow-ups describe severe mood effects resolving over periods from about a month to much longer, alongside positive and null reports.
Self-selection, indication/dose differences, deleted identities and no isomer measurements. One prolonged-recovery account included concurrent TRT followed by TRT withdrawal; mood-recovery time is not isolated clomiphene causation or parent clearance.
- Clomid experiences (opens in a new tab)Actual OP and relevant replies through line 265, including MistakeLogical7593 at 198–235: 25 mg/day for four months, concurrent TRT for the first three months, then TRT withdrawal and adverse mood/recovery updates. Other users report improvement, nulls and adverse outcomes; deleted-user comments cannot all be linked confidently to one person.Self-selected reports, deleted material, variable sex/indication/dose and co-treatments; follow-up timing describes recovery experiences, not isomer clearance.
- 6 weeks on Clomid — great numbers, mixed symptom response (opens in a new tab)OP and same-author replies: 25 mg every other day; total testosterone 222 to 686 ng/dL and estradiol 24 to 42 at six weeks; early two-to-three-week symptom improvement later dulled but remained above baseline.One recent uncontrolled male report. Lab change and subjective change cannot identify either isomer’s terminal half-life or predict another person’s response.
What people say
- Libido / energy / vitality: Common responder reports when low-T symptoms track with better morning TT and free T — not universal; high E2 or mood sides can blunt the feel. forum
- PCT / post-AAS recovery: Classic bodybuilding SERM for post-cycle HPTA restart charts, often paired with tamoxifen and sometimes an hCG bridge. forum
- Oral convenience: Daily or every-other-day tablets — no injections vs hCG-heavy or injectable-TRT protocols. Standard 50 mg scored tabs make 25 mg splits easy. forum
- TRT alternative narrative: Men’s-health clinics market it for men who want symptom relief and higher T without committing to lifelong exogenous T or who want to keep fertility open. forum
- Female ovulation (labeled): Multi-day oral courses early in the cycle are the approved indication — designed to recruit follicles and trigger ovulation under monitoring. trial
- Male T rise (off-label series): Clinic cohorts commonly report total T roughly doubling from low/borderline baselines into mid-normal (examples: means from ~230–250 ng/dL into ~550–610 ng/dL range talk, with target bands often near ~550 ± 50 ng/dL). trial
- LH/FSH up, not shut down: Opposite of exogenous TRT on the axis — gonadotropins increase, which is the fertility and testicular-volume argument vs gels/injectables alone. trial
- Fertility vs TRT: Discussed as raising T while supporting (or at least not crushing) spermatogenesis — unlike exogenous testosterone, which commonly suppresses sperm production. Full spermatogenesis cycles are often framed around ~90–108 days of continuous exposure for semen-parameter evaluation. trial
- Long clinic series: Multi-month to multi-year male cohorts (e.g. mean treatment ~19 months in young hypogonadal series; multi-year follow-ups with TT held in the ~500s) report sustained eugonadism and symptom gains under lab follow-up. trial
- T/E ratio improvement: Some series report improved testosterone-to-estradiol ratio alongside the T rise (classic example: mean T/E from ~8.7 to ~14.2 at 4–6 weeks). trial
- Lower polycythemia signal vs TRT (discussed): Observational comparisons report much lower hematocrit elevation rates on clomiphene than on injectable testosterone; still monitored in long male use. trial
Doses people talk about
- Alternate male starts: 50 mg every other day, or 25 mg daily, are equally common clinic openers when baseline TT sits in the mid-300s ng/dL. forum
- Upper-end talk: 100 mg/day appears as a ceiling in some male-infertility dosing notes; community culture often prefers not living above ~50–100 mg/day because sides and E2 pressure climb and returns may flatten. forum
- PCT chart — moderate taper (very common forum pattern): ~50 mg/day for 2 weeks, then 25 mg/day for 2 weeks (sometimes written as 4-week block). forum
- PCT chart — higher front-load: Examples include 100 mg/day week 1 → 50 mg/day weeks 2–3 → 25–50 mg/day week 4; or 50 mg/day weeks 1–2 then 25 mg/day weeks 3–4. Schedules vary by cycle length and suppression depth. forum
- PCT chart — aggressive dual-SERM (Scally-style discussion): Clomiphene 2 × 50 mg (100 mg/day) for ~30 days plus tamoxifen 2 × 20 mg (40 mg/day) for ~45 days, often after or with an hCG bridge (example cited: 2000 IU EOD × ~20 days). Framed as aggressive, not a default beginner PCT. forum
- PCT + Nolvadex pair (standard bro stack): Clomid 50→25 mg taper alongside tamoxifen 40→20 mg taper over ~4 weeks is one of the most-copied dual-SERM templates. forum
- EOD logic in discussion: Long zuclomiphene persistence and historical multi-day composite half-life figures are often cited to explain clinically common every-other-day male schedules and a preference over daily high doses during chronic use. This is reported rationale and preference, not a kinetic demonstration of the best schedule or lower risk. forum
- Titrate to labs + goals: Adjust by morning TT/free T, E2, LH/FSH, symptoms, semen goals, and sides — not by a fixed internet spreadsheet alone. forum
- With food / timing: Taken with or without food in practice; consistent same-time habit is the common adherence rule. No special cold-chain timing. forum
- 2025–26 male start still 25 mg EOD: Clinic-style 25 mg every other day remains the copied opener; 25 mg every day is what 2025 switch threads blame for late brain fog and dead libido. forum
- Clomid + TRT leftover charts: Some 2025 clinic logs still run 25 mg Clomid EOD (or 50 mg twice a week) next to low-dose testosterone. Forum pushback is that you are stacking a SERM on exogenous T and should pick a lane. forum
- India “En-Clofert” trap: 2025 r/Testosterone posts warn that En-Clofert-class tablets are still racemic clomiphene (enclo-equivalent milligrams plus leftover zuclomiphene), not pure enclomiphene. Name is not isomer proof. forum
- PCT 50 → 25 mg taper still the copied 4-week block: 2026 PCT writeups have not retired Clomid; they just offer enclomiphene as a swap. Dual Clomid + Nolvadex remains the old template. forum
- Male hypogonadism band (clinic series): Roughly 25 mg every other day up to 50 mg daily is the most-repeated effective band; some infertility write-ups allow up to ~100 mg daily as a discussed maximum. trial
- Classic male start (Katz-style and many clinics): 25 mg every other day, titrated toward 50 mg every other day against a TT target (example target talk ~550 ± 50 ng/dL). In one young-male series, ~70% stayed on 25 mg EOD and the rest used 50 mg EOD over mean ~19 months. trial
- Daily 25–50 mg: Late-onset hypogonadism reviews often quote 25–50 mg per day with TT rise by ~4 weeks. trial
- Tablet math: Branded/generic product is typically a 50 mg scored tablet — split for 25 mg; compounding pharmacies sometimes supply other strengths. trial
- Framing: Discussed / trial / label-reported ranges only — not medical advice, not a prescription, not product endorsement. forum
- Female labeled start: 50 mg orally once daily for 5 days (one 50 mg tablet). Often started on or about cycle day 5 after spontaneous or progestin-induced bleeding (clinic practice also uses day 3–5 starts). trial
- Female labeled step-up: If no ovulation on 50 mg, a subsequent cycle may use 100 mg daily (two 50 mg tablets as a single daily dose) for 5 days. Lower 12.5–25 mg/day courses appear in sensitive patients or those who form large cysts. trial
- Female ceiling culture: Label and practice discourage indefinite escalation; multi-pregnancy / multi-follicle risk rises with higher stimulation — limited course counts under monitoring. trial
How it may feel
- Days 1–7: Often little subjective change. Mild headache, hot-flash warmth, GI unease, or early mood edge can show before labs move. forum
- Weeks 1–2: Some note early energy or libido ticks; many feel nothing yet. Clinics usually wait for a longer bloodwork window rather than judging on week-1 feel. forum
- Weeks 3–6: Standard first bloodwork checkpoint in clinic talk — morning TT/free T, LH, FSH, sensitive E2, CBC/hematocrit, lipids; often SHBG and PSA context by age/risk. Symptom lag can trail lab gains by another 2–4 weeks. forum
- Weeks 4–8: Typical “does this work for me?” window for energy, libido, and sexual scores in male discussion. forum
- Months 2–6: Stable responders describe held libido/energy if labs stay mid-normal and E2 is tolerable; partial responders reassess diagnosis, sleep/weight/apnea, opioids, or residual androgen suppression. forum
- No meaningful lab change ~4–8 weeks: Re-lab and rethink — primary hypogonadism, ongoing opioids, untreated sleep apnea, or residual exogenous-androgen suppression won’t behave like clean secondary cases. forum
- Week 1 “switched on,” week 6–8 crash: 2025 r/enclomiphene and r/Testosterone logs still describe a honeymoon (energy, libido, less fog) on 25 mg daily Clomid, then a libido hole and brain fog around weeks 6–8. Dropping to 25 mg EOD often clears fog more than libido. forum
- Switch-to-enclo feel: 2025–26 male threads treat compounded enclomiphene as the next move when racemic Clomid feels flat, foggy, or emotionally off. Zuclomiphene washout is discussed as 3–4 weeks before judging the cleaner isomer — not overnight. forum
- “Fuck Clomid, write enclo” vs UK/clinic lock-in: r/Testosterone 2025 comments tell people to drop Clomid for compounded enclomiphene; UK and some US clinic logs stay on Clomid because enclo is not locally prescribed. Access, not a head-to-head feel trial. forum
- ~4 weeks: Common cited window for measurable TT elevation in male hypogonadism write-ups (some sources say T rise is clear by ~4 weeks on usual male doses). trial
- Female cycle timing: Short 5-day early-cycle course (often starting ~day 3–5 of menses), then ovulation monitoring — not a steady-state “feel over months” model. trial
Around the dose
- Clock: Same time each dose, with or without food. Not a bedtime GH pin. forum
- Don’t judge week 1: 2025 logs still call early confidence a placebo window. First real checkpoint is morning labs around weeks 4–6 plus how libido/mood feel after that. forum
- EOD vs daily is the habit fight: Men who crash on 25 mg daily often keep the same 25 mg tablet and skip days rather than adding an AI the first week. forum
- After a Clomid → enclo switch: Threads say wait through zuclomiphene’s long tail (weeks, not days) before deciding enclo “does nothing.” forum
- Vision rule still wins the night: Blur, floaters, flashes, or light sensitivity = stop-and-get-eyes-checked talk, not “push through to the next blood draw.” trialforum
Cycles people discuss
- PCT model: Discrete multi-week blocks (commonly ~3–6 weeks of SERM, sometimes longer) timed after the last exogenous androgen clears enough for endogenous restart — start delay depends on ester half-life (e.g. longer wait after long esters). forum
- hCG bridge debate: Many PCT charts run hCG during the cycle tail or the first ~2–3 weeks of PCT, then SERMs alone — to stimulate testes before pure SERM restart. Others skip hCG on lighter cycles. forum
- Time-on / time-off (male continuous): Some users pause after stable labs and reassess; others stay on while benefits and labs justify. No single universal “8 weeks on / 8 off” standard for hypogonadism use. forum
- Re-runs: Restart when symptoms and labs slip after a break is commonly described. forum
- Failure to respond: Non-response after adequate trial prompts re-diagnosis (primary vs secondary), adherence check, and discussion of hCG, gonadorelin, or exogenous T pathways — not endless dose escalation. forum
- Female labeled model: Short 5-day courses per menstrual cycle; repeat only under monitoring; dose step-up only if no ovulation on prior course. Not continuous daily therapy. trial
- Male clinic / TRT-alternative model: Often continuous multi-month daily or EOD dosing with labs at ~4–6 weeks, then every 3–6 months when stable. Multi-year continuous series exist in the literature. trial
- Fertility courses: Often planned around ≥1 full spermatogenic cycle (~3 months) before judging semen-parameter response. trial
Timing
- EOD discussion: Long zuclomiphene and tissue persistence are often cited as a rationale for 25–50 mg every-other-day male schedules and maintaining axis effects without daily high peaks. That is reported clinical/community reasoning, not proof that parent kinetics establish an optimal interval, equivalent hormone response, or lower adverse-effect risk. forum
- Lab recheck cadence: ~3–6 weeks after start or dose change; then periodic (often every 3–6 months) on long male use. forum
- Composite / historical half-life talk: Clomiphene is often summarized with a multi-day half-life (~5 days is a common teaching figure; some clinical notes cite ~10–14-day effective ranges because of the long isomer). These are historical summaries, not one clean composite terminal half-life established by the checked sources. Classic label data recovered only about half of oral radiolabel in urine/feces by ~5 days; radiolabel recovery is not intact-parent elimination. trial
- Enclomiphene (trans): The shorter-persisting, anti-estrogenic isomer drives the LH/FSH push. Earlier isomer notes quote a ~10–10.5-hour terminal half-life and a ~2–3-hour peak; the formulation/population basis of that half-life estimate is not established by the checked study. In nine women with PCOS after one 50 mg oral clomiphene dose, mean enclomiphene Tmax was 3 hours, but the flat terminal tail prevented a reliable conventional terminal half-life estimate. trial
- Zuclomiphene (cis): Much longer-persisting: older notes commonly cite ~30 days, including multi-week / ~30–50-day half-life talk, and accumulation on chronic dosing. The label reports detectability beyond a month after treatment, but detectability does not establish those figures as a terminal half-life. The checked single-dose PCOS study could not reliably estimate that terminal parameter or define chronic male accumulation. trial
- Hormone lag: LH/T changes and side-effect tails lag last-pill timing — labs and feel are not same-day readouts. trial
- Female timing: 5-day early-follicular courses target recruitment windows, not steady-state drug levels. trial
- Washout implications: After long male use, zuclomiphene accumulation means sides or residual estrogenic tone can trail off slowly — relevant when switching to pure enclomiphene or stopping. trial
More on what it is
- Why men search it: Raise endogenous testosterone, LH, and FSH without the testicular shutdown of exogenous TRT — framed as “stimulate your own production” for secondary hypogonadism, fertility, and classic bodybuilding PCT. forum
- What it is: Oral selective estrogen receptor modulator (SERM), sold as clomiphene citrate (Clomid and generics). A non-racemic mix of two geometric isomers — roughly ~62% enclomiphene (trans) and ~38% zuclomiphene (cis) in typical tablet discussion (label notes cis content in the ~30–50% band). Not a peptide, not exogenous testosterone. trial
- Approved use: FDA-labeled for female anovulatory / oligo-ovulatory infertility — multi-day oral courses to induce ovulation. Long clinical history under brand Clomid and generics. trial
- Mechanism (plain): Competitive estrogen-receptor antagonism at hypothalamus/pituitary → less negative feedback → more GnRH drive → more LH/FSH → ovaries ovulate (women) or Leydig cells make more T and Sertoli side supports spermatogenesis (men). trial
- Isomer split (core bro fact): Enclomiphene is the shorter-lived anti-estrogenic workhorse that drives the LH/FSH/T rise; zuclomiphene is longer-lived, more estrogen-agonist-leaning, and is the isomer people blame for mood, vision, and lingering estrogenic drama. trial
- Evidence honesty: Female ovulation use is labeled. Male hypogonadism / infertility / PCT use is off-label — supported by observational series, clinic cohorts, meta-analyses of mild AEs, and dense forum charts, not a male FDA indication. trial
- Who it can work for (discussed): Secondary / hypogonadotropic-leaning low T with intact testes and a responsive HPG axis. Primary testicular failure and fully suppressed post-heavy-AAS axes are commonly called non- or weak-responders. trial
- Research-only framing here: Community, clinic, and trial ranges are descriptive — not dosing advice, not a prescription, not a claim of safety for unsupervised use. forum
Stacks
- Solo male therapy: Often run alone with sleep, lifting, weight management, and periodic labs — first-line clinic pattern for many secondary-hypogonadism candidates. forum
- + Tamoxifen (Nolvadex): Classic dual-SERM PCT pair; tamoxifen adds breast-tissue SERM coverage and a second LH/FSH push in forum doctrine. forum
- + hCG: Male fertility and PCT protocols when dual stimulation is wanted (LH-mimetic testicular push + SERM central unblock). On-cycle hCG to limit atrophy is a separate common pattern. forum
- + Aromatase inhibitor (anastrozole / exemestane): Sometimes added if E2 runs high with nipple sensitivity or gyno talk; over-suppression of estrogen (joint ache, flat libido, lipid hit) is the recurring caution. forum
- Clomid vs Clomid+AI debate: Some prefer to lower clomiphene dose rather than add an AI; others microdose AI only when sensitive E2 is clearly high. forum
- + Gonadorelin: Discussed in advanced fertility / HPTA protocols as a GnRH-pulse alternative or adjunct — less common than hCG in pure bro PCT charts. forum
- Lifestyle stack: Sleep, resistance training, body-fat loss, and sleep-apnea treatment are repeatedly credited as co-drivers of whether labs and symptoms actually improve. forum
- Not a steroid cycle stack for “gains”: Discussed as recovery / hormone-axis support, not as a mass-building PED itself. forum
- Switch / compare to enclomiphene: Growing clinic trend to prefer pure enclomiphene for chronic male use to drop the zuclomiphene tail; comparative series report fewer libido/energy/mood AE signals on enclo. trial
Access talk
- Generic 50 mg scored Clomid/tabs are the cheap shelf: Split for 25 mg. This is the FDA-labeled female ovulation product used off-label in men — not a male TRT brand. trialforum
- Compounded enclomiphene is the 2025–26 upgrade path: Men’s-health telehealth and compounding pharmacies sell 6.25 / 12.5 / 25 mg enclo. Some US clinicians still refuse it because it is not FDA-approved for hypogonadism and keep patients on racemic clomiphene. forum
- UK / local-formulary lock-in: 2025 r/Testosterone UK logs stay on Clomid when enclo is not prescribed. Geography, not a preference trial. forum
- India-mart “enclo” tablets: En-Clofert-class products discussed as clomiphene citrate labeled in enclomiphene milligrams — still the zu isomer. Gray oral SERMs are an identity problem, not a pharmacy generic. forum
Labs people mention
- First male panel (~4–6 weeks): Morning total T, free T, LH, FSH, sensitive estradiol, SHBG, CBC/hematocrit, lipids. Clinics often recheck every 3–6 months once stable. forum
- T/E ratio lore: 2025–26 enclo/Clomid threads argue a roughly 1:10–1:18 total-T:E2 ratio and tell people not to crush E2 just because it sits above a 40–50 pg/mL lab flag while T also rose. Ratio talk is forum arithmetic, not a labeled target. forum
- Fertility endpoint is semen, not week-4 T: ~3 months (one spermatogenic cycle) before judging sperm parameters. trialforum
- If T does not move: Re-think primary hypogonadism, opioids, apnea, or leftover exogenous androgens — not automatic 100 mg/day. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Estrogenic / breast (men): Nipple tenderness, breast sensitivity, or gyno talk when E2 rises with the T rise; zuclomiphene’s agonist lean is often blamed in community lore. Sensitive E2 monitoring is the usual clinic counter. forum
- Testicular sensations: Mild ache, fullness, or enlargement reports as gonadotropins rise. forum
- No-labs risk: Long unsupervised use without TT/E2/LH/FSH/CBC/lipids is a structural caution in every serious write-up. forum
- Vision (stop-and-evaluate): Blurred vision, spots/scotomata, flashes, or light sensitivity — classic SERM caution for clomiphene; labeled and clinic guidance is to discontinue and get evaluated if visual symptoms appear or persist. Male series put visual changes in roughly the ~1–2% band. trial
- Mood: Irritability, anxiety, low mood, emotional lability, or agitation — more infamous in female short courses, but men still report mood change as one of the more common AEs (example long-term male series: mood ~2.3% of reported AEs; one comparative series found higher AE rates on racemic clomiphene than enclomiphene). trial
- Headache / hot flashes / dizziness: Among the most frequent mild effects in both sexes — flushing, hot flashes, headache, lightheadedness. trial
- Libido paradox: Minority report lower libido or blunted sexual function despite higher TT — attributed to E2 imbalance, mood sides, or SERM effects at tissue level. Comparative work has flagged decreased libido more often on clomiphene than enclomiphene. trial
- GI: Nausea, abdominal discomfort, occasional vomiting. trial
- Acne / weight / flushing: Low-single-digit % reports in long male follow-up (e.g. weight gain ~1.3%, acne ~0.5% in one ~2.5-year cohort). trial
- Female-specific risks: Multi-follicular recruitment, ovarian cyst formation, multi-pregnancy risk, endometrial effects, and stronger mood-swing reputation on labeled ovulation courses. trial
- Hematocrit: Polycythemia rates are discussed as much lower than injectable TRT (example: ~0.25% in a multi-year male clomiphene cohort vs teens of % on injectables), but CBC monitoring every 6–12 months still appears in careful clinic notes; AI combos may raise the rate slightly. trial
- PSA / lipids / long-term labs: Long male use is generally described as not driving large PSA spikes in series, but age-appropriate PSA, lipid panels, and symptom review remain part of responsible monitoring talk. trial
- Rare serious: Very rare azoospermia reports exist in fertility literature; cardiac/thromboembolic events were not prominent in the male series commonly cited — still not “zero risk.” trial
- Overall male AE rates (honest range): Meta-analytic mild-AE talk ~2–3% in some fertility pools; a ~393-man multi-year review ~9% any AE; a 2024 comparative series reported substantially higher AE frequency on clomiphene (~47%) vs enclomiphene (~14%) in that cohort — methodology differs, so quote as range not a single universal %. trial
- Primary hypogonadism caveat: Will not rescue failed testes the way it helps secondary cases — wrong diagnosis wastes time and exposes to sides. trial
- Not risk-free / not approved for male indication: Off-label male use remains research- and clinic-context; vision and mood sides are the non-negotiable “know before you discuss” flags. trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.